First-Line Therapy for Metastatic Non-Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches

摘要

The treatment paradigm, for metastatie non-small cell lung cancer (NSCLC) has changed dramatically in the past few years. At JADPRO Live 2019, Joshua Baumi, MOD, and Christina Knepley, CRNP, of Perm Medicine, discussed the use of biomarkers to guide the selection of first-line therapy for metastatic NSCLC. The presenters also evaluated clinical data supporting first-line treatment with targeted and immune checkpoint in hibitors and outlined effective management strategies for adverse events associated with these agents.